Latest & greatest articles for ciprofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ciprofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ciprofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ciprofloxacin

1. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial (PubMed)

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial Antibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal (...) meningitis.In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random

Full Text available with Trip Pro

2018 EvidenceUpdates

2. Ciprofloxacin (Cetraxal) - treatment of acute otitis externa

Ciprofloxacin (Cetraxal) - treatment of acute otitis externa Final Appraisal Recommendation Advice No: 1218 – July 2018 Ciprofloxacin (Cetraxal ® ) 2 mg/ml ear drops solution in a single dose container Limited submission by Aspire Pharma Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1343), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (...) (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Ciprofloxacin (Cetraxal ® ) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact

2018 All Wales Medicines Strategy Group

3. Ciprofloxacin

Ciprofloxacin Top results for ciprofloxacin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ciprofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

4. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial

Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP.This is an investigator-initiated open-label (...) randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein ≤1.5 g/dL or the presence of history of SBP. Ascitic polymorphonucleated cell count needed to be <250/mm3. Patients were randomly assigned into norfloxacin daily or ciprofloxacin weekly group, and followed-up for 12 months. Primary endpoint was the prevention of SBP.One hundred twenty-four patients met

2018 EvidenceUpdates

5. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.Patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14- or 28-day on/off treatment cycles for 48 weeks (...) . Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and α level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.Patients were randomised to ciprofloxacin DPI (14 days on/off (n=176) or 28 days on/off (n=171)) or placebo (14 days on/off (n=88) or 28 days on/off (n=86)). The exacerbation rate was low across treatment arms (mean±sd 0.6±0.9). Active treatment showed trends to prolonged time to first exacerbation

2018 EvidenceUpdates

6. Ciprofloxacin ear drops (Cetraxal) - acute otitis externa

Ciprofloxacin ear drops (Cetraxal) - acute otitis externa Published 9 April 2018 Product Update: ciprofloxacin ear drops solution, single dose container 2mg/mL (Cetraxal ® ) SMC No 1320/18 Aspire Pharma Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ciprofloxacin ear drops (Cetraxal ® ) are accepted for restricted use within NHS Scotland. Indication under review: treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. SMC restriction: when off-label or unlicensed ciprofloxacin formulations would otherwise be used. Ciprofloxacin eye drops (used off-label) or unlicensed ciprofloxacin ear drops have been in use in NHS Scotland for this indication

2018 Scottish Medicines Consortium

7. Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin (PubMed)

Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin We have previously reported that supplementation of exogenous glutathione (GSH) promotes ciprofloxacin resistance in Escherichia coli by neutralizing antibiotic-induced oxidative stress and by enhancing the efflux of antibiotic. In the present study, we used a whole-genome microarray as a tool to analyze the system-level transcriptomic changes of E. coli (...) on exposure to GSH and/or ciprofloxacin. The microarray data revealed that GSH supplementation affects redox function, transport, acid shock, and virulence genes of E. coli. The data further highlighted the interplay of multiple underlying stress response pathways (including those associated with the genes mentioned above and DNA damage repair genes) at the core of GSH, offsetting the effect of ciprofloxacin in E. coli. The results of a large-scale validation of the transcriptomic data using reverse

Full Text available with Trip Pro

2018 mSystems

8. Ciloxan (Ciprofloxacin) - otitis externa or otitis media

Ciloxan (Ciprofloxacin) - otitis externa or otitis media 1/16 The legally binding text is the original French Version TRANSPARENCY COMMITTEE OPINION 19 October 2011 CILOXAN 3 mg/ml, ear drops, solution B/1 bottle of 5 ml (CIP code: 3601303) Applicant: ALCON FRANCE Ciprofloxacin ATC code: S02AA (antibiotic from the fluoroquinolone family) List I Date of Marketing Authorisation: 28 November 2002, amendment of 14 May 2008 Reason for request: Inclusion on the list of medicines refundable (...) by National Health Insurance and approved for hospital use. Medical, Economic and Public Health Assessment Division 2/16 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient Ciprofloxacin 1.2. Indication "Antibiotic treatment for adults and children from 1 year: - for acute otitis externa - for purulent otorrhea of the mastoid cavity and chronic suppurative otitis media with tympanic perforation. Consideration should be given to official guidance on the appropriate use of antibacterial agents

2014 Haute Autorite de sante

9. Ciprofloxacin

Ciprofloxacin USE OF CIPROFLOXACIN IN PREGNANCY 0344 892 0909 USE OF CIPROFLOXACIN IN PREGNANCY (Date of issue: June 2017 , Version: 3.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The quinolones (including ciprofloxacin, levofloxacin (...) , moxifloxacin, nalidixic acid, norfloxacin and ofloxacin) are broad-spectrum synthetic antibiotics used in the treatment of a wide variety of infections including those of the urinary tract, respiratory-tract, gastro-intestinal system, bones and joints, as well as gonorrhoea, chlamydia and septicaemia. Ciprofloxacin is also used in the treatment or post-exposure prophylaxis of anthrax. No increased risk of congenital malformations overall, low birth weight, preterm delivery, intrauterine death or neonatal

2014 UK Teratology Information Service

10. Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou (PubMed)

Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy in low-risk febrile neutropenic patients with cancer.Inclusion criteria were cancer, febrile (...) neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation. Early discharge was encouraged when a set of predefined criteria was met. Patients received either moxifloxacin (400 mg once daily) monotherapy or oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily). The trial

2013 EvidenceUpdates

11. Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness

Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2012 CONTEXT AND POLICY ISSUES The potential use of anthrax as a biological terrorist attack has

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. (PubMed)

Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. Although fluoroquinolones remain the most reliable urinary antimicrobial, resistance rates have increased and effective fluoroquinolone-sparing antimicrobials are needed.To determine whether cefpodoxime is noninferior to ciprofloxacin for treatment of acute cystitis.Randomized, double-blind trial of 300 women aged 18 to 55 years with acute uncomplicated cystitis comparing ciprofloxacin (...) (n = 150) with cefpodoxime (n = 150); patients were from a student health center in Seattle, Washington, and a referral center in Miami, Florida. The study was conducted from 2005 to 2009 and outcomes were assessed at 5 to 9 days and 28 to 30 days after completion of therapy. Intent-to-treat and per-protocol analyses were performed; 15 women in the ciprofloxacin group and 17 women in the cefpodoxime group were lost to follow-up.Patients were given 250 mg of ciprofloxacin orally twice daily for 3

Full Text available with Trip Pro

2012 JAMA

13. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. (PubMed)

Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Acute pyelonephritis is a common infection in adult women, but there is a paucity of controlled trials of its treatment and the optimum duration of antibiotic treatment has not been properly defined. We compared the efficacy of ciprofloxacin for 7 days and 14 days in women with community-acquired acute pyelonephritis.In a prospective (...) , non-inferiority trial undertaken at 21 centres of infectious diseases in Sweden, women (aged ≥18 years) who were not pregnant and had a presumptive diagnosis of acute pyelonephritis were randomly assigned to oral treatment with ciprofloxacin 500 mg twice daily for 7 days or 14 days. The first week was open label. A computer-generated randomisation list in block sizes of two was used for treatment allocation in a 1:1 ratio. The study was double-blind and placebo-controlled during the second week

2012 Lancet

14. Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review

Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Chui D, Cheng L, Tejani AM CRD summary This review reported that there was insufficient (...) evidence to determine whether twice daily doses of 750mg enteral or 400mg intravenous ciprofloxacin were more effective in adult patients who received enteral feeds. Despite a risk of publication bias and lack of a validity assessment, the findings of the review appear reliable given the very limited evidence. Authors' objectives To compare the effects of 750mg enteral and 400mg intravenous ciprofloxacin for adult patients receiving enteral feeding. Searching EMBASE and MEDLINE were searched for fully

2009 DARE.

15. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections

Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Paladino J A, Gilliland-Johnson K K, Adelman M H, Cohn S M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study compared the cost-effectiveness of two antibiotic regimens, ciprofloxacin-metronidazole versus piperacillin-tazobactam, for the treatment of adult patients with complicated intra-abdominal infections requiring surgical intervention

2008 NHS Economic Evaluation Database.

16. Ciprofloxacin hydrochloride & dexamethasone otic suspension - Otitis media with otorrhea & otitis externa, acute

Ciprofloxacin hydrochloride & dexamethasone otic suspension - Otitis media with otorrhea & otitis externa, acute Common Drug Review CEDAC Meeting – September 19, 2007 Page 1 of 2 Notice of CEDAC Final Recommendation – October 18, 2007 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION CIPROFLOXACIN HCL and DEXAMETHASONE OTIC SUSPENSION (Ciprodex ® – Alcon Canada) Description: Ciprodex ® is a combination of ciprofloxacin HCl and dexamethasone that is indicated for the local treatment (...) of acute otitis media with otorrhea through tympanostomy tubes in pediatric patients aged six months and older and for acute otitis externa in pediatric and adult patients aged one year and older. The review of ciprofloxacin HCl/dexamethasone (Ciprodex ® ) by the Common Drug Review was in response to a Request for Advice from the Advisory Committee on Pharmaceuticals which questioned if the CEDAC recommendation of January 26, 2005 that ciprofloxacin HCl/dexamethasone (Ciprodex ® ) not be listed, should

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

17. Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US

Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Schmier J K, Waycaster C R, Wall G M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study compared the cost-effectiveness of ciprofloxacin-dexamethasone ear drops with oral amoxicillin-clavulanic acid for the treatment of patients with acute otitis media in the tympanostomy tube (AOMT

2007 NHS Economic Evaluation Database.

18. A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh

A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Article Text Therapeutics A single dose of azithromycin was more

2006 Evidence-Based Medicine (Requires free registration)

19. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. (PubMed)

Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Single-dose ciprofloxacin is effective for the treatment of severe cholera in adults. We assessed whether single-dose ciprofloxacin would be as effective as 3-day, 12-dose erythromycin in achieving clinical cure in children with severe cholera.We did a randomised, open label, controlled trial in children age 2-15 years with V cholerae O1 or O139 present in stool on dark-field microscopy (...) . Children received either a single 20 mg/kg dose of ciprofloxacin (n=90) or 12.5 mg/kg of erythromycin (n=90) every 6 h for 3 days, and remained in hospital for 5 days. The primary outcome was clinical success of treatment, defined as cessation of watery stools within 48 h of start of drug treatment. Analysis was per protocol. This study is registered with the ClinicalTrials.gov Protocol Registration System at http://www.clinicaltrials.gov (registration number NCT 00142272) [corrected]Of 180 children

2005 Lancet

20. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. (PubMed)

Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. The high prevalence of resistance to trimethoprim-sulfamethoxazole and other antimicrobials among Escherichia coli causing acute cystitis in women has led to increased use of alternative antibiotics. One such antibiotic, amoxicillin-clavulanate, has not been well studied.To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen (...) of ciprofloxacin in the treatment of acute cystitis in women. The primary study hypothesis was that the amoxicillin-clavulanate and ciprofloxacin treatment groups would differ in clinical cure.Randomized, single-blind treatment trial of 370 women, aged 18 to 45 years, with symptoms of acute uncomplicated cystitis and a urine culture with at least 10(2) colony-forming units of uropathogens per milliliter from a university student health center or a health maintenance organization.Women were randomly assigned

Full Text available with Trip Pro

2005 JAMA